Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RM-718 in Obesity, Hypothalamic Obesity, and Prader-Willi Syndrome
NCT06239116Phase 2Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RM-718 in obesity, hypothalamic obesity (HO) and Prader-Willi syndrome (PWS) (17 cohorts), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events. Started Mar 2024; status: active, not recruiting.
02
Drugs
RM-718
03
Conditions
obesityhypothalamic obesity (HO)Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT06239116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239116.